EQS-Adhoc
Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2024: Net sales and earnings below the strong prior-year quarter – Annual forecast confirmed
- Dräger Q1 2024: Net sales & earnings below prior year, annual forecast confirmed
- Net sales down 2.6%, safety division up 10%, medical division down 10.4%
- Order intake up 1.5%, safety division up 6.1%, medical division down 1.9%
EQS-Ad-hoc: Drägerwerk AG & Co. KGaA / Key word(s): Preliminary Results/Forecast Ad-hoc notification in accordance with Sec. 17 of the MAR |
Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2024: Net sales and earnings below the strong prior-year quarter – Annual forecast confirmed
Lübeck, April 15, 2024 – In the first quarter, which is traditionally weak for Dräger, the Company once again achieved a positive operating result of around EUR 15 million based on preliminary calculations. However, earnings and net sales declined as expected after the exceptional improvement in the same quarter of the previous year. In the first quarter of 2023, Dräger had benefited from catch-up effects as a result of the noticeable improvement in delivery capability. In addition, a surge in demand for ventilators in China had led to higher net sales. As expected, both effects were absent in the first quarter of 2024.
Net sales in the first quarter of 2024 decreased by 2.6 percent (net of currency effects; nominal: -3.3 percent) to around EUR 736 million (Q1 2023: EUR 761.1 million). The safety division continued its growth and recorded an increase of 10.0 percent (net of currency effects; nominal: 9.3 percent) to around EUR 318 million (Q1 2023: EUR 291.2 million). The medical division saw a decline of 10.4 percent (net of currency effects; nominal: -11.2 percent) to around EUR 417 million (Q1 2023: EUR 469.9 million), which is attributable in particular to the two base effects in the prior year. The Group's gross margin increased to around 45.3 percent (Q1 2023: 45.0 percent). Earnings before interest and taxes (EBIT) amounted to around EUR 15 million (Q1 2023: EUR 29.1 million). The EBIT margin amounted to around 2.0 percent (Q1 2023: 3.8 percent).